Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 406 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07501351RecruitingPhase 2
Comparing two therapies for advanced liver cancer after first treatment fails
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Guangzhou, GuangdongAges 18–75 - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75 - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT06447623RecruitingPhase 3
Apatinib plus CDK4/6 inhibitor for first-line HR+/HER2- SNF4 breast cancer
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07306273RecruitingPhase 2
Testing IRE and an immunotherapy drug for advanced pancreatic cancer
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07408505Recruiting
New appetite drug for weight loss in advanced pancreatic cancer
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
JinanAges 18–75 - NCT06521866RecruitingPhase 2
Study of serplulimab plus standard therapy for advanced colorectal cancer
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Fuzhou, FujianAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07165951RecruitingPhase 3
Study of new drug combo for first treatment of advanced pancreatic cancer
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
Hefei, AnhuiAges 18–75 - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT07185997RecruitingPhase 3
Testing firmonertinib for a type of lung cancer with rare EGFR mutations
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
Fullerton, CaliforniaAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT07733115RecruitingPhase 2
Drug combo for advanced bile duct cancer
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
ShanghaiAges 18–75 - NCT07502300RecruitingPhase 3
New drug combo for advanced small cell lung cancer
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Zhengzhou, HenanAges 18 years+ - NCT07429773Recruiting
Immune markers in stubborn pelvic pain
This study looks at the immune system's response in people with chronic pelvic pain that hasn't gotten better with first treatments. By measuring certain immune markers, the researchers hope to better understand why the pain persists and find new ways to help.
Nice, Alpes-MaritimesAges 18–40 - NCT06038461RecruitingPhase 1/Phase 2
Surufatinib with chemo for advanced neuroendocrine tumors
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 406 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.